Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response

Fertil Steril. 2006 Jan;85(1):247-50. doi: 10.1016/j.fertnstert.2005.07.1280.

Abstract

Various studies have compared the efficacy of GnRH agonists (GnRH-a) and antagonists (GnRH-ant) for controlled ovarian stimulation (COS) in women undergoing IVF. Nevertheless, few data are available about the use of GnRH-ant in poor responders. Here, a flexible protocol providing a gradual increase in the dose of GnRH-ant in association with recombinant LH (rec-LH) administration is compared with the standard GnRH-a flare-up protocol in 133 women at risk for poor ovarian response. The mean number of metaphase 2 oocytes (primary end point) was significantly higher in the antagonist group (5.73 +/- 3.57 vs. 4.64 +/- 2.23, respectively; P<.05).

Publication types

  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Drug Therapy, Combination
  • Female
  • Fertilization in Vitro
  • Gonadotropin-Releasing Hormone / agonists*
  • Gonadotropin-Releasing Hormone / antagonists & inhibitors*
  • Humans
  • Infertility, Female / drug therapy*
  • Infertility, Female / epidemiology
  • Luteinizing Hormone / administration & dosage*
  • Ovulation Induction / methods*
  • Pregnancy
  • Pregnancy Rate
  • Prospective Studies
  • Recombinant Proteins / administration & dosage
  • Risk Factors

Substances

  • Recombinant Proteins
  • Gonadotropin-Releasing Hormone
  • Luteinizing Hormone